ROCKVILLE, Md., Nov. 01, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary
NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 8, 2017 at 4:30
p.m. ET to discuss its financial results for the quarter ended September 30, 2017 and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode
96009722. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at
www.regenxbio.com. The recorded webcast will be available for approximately 30 days following
the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene
therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and
its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline
of product candidates in multiple therapeutic areas.
CONTACT:
Investors
Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com
Media
Adam Pawluk, 202-591-4063
apawluk@jpa.com